Number | Mortality % (95 % CI) | Crude MRR (95 % CI) | Adjusteda MRR (95 % CI) | |
---|---|---|---|---|
CHF | ||||
Absent | 2248 | 30.4 (28.6–32.4) | 1.00 (ref.) | 1.00 (ref.) |
Present | 390 | 44.6 (39.8–49.7) | 1.60 (1.36–1.89) | 1.24 (1.04–1.48) |
CHF-related conditions | ||||
CHF absent | 2248 | 30.4 (28.6–32.4) | 1.0 (ref.) | 1.0 (ref.) |
Cardiomyopathy | 52 | 30.8 (20.1–45.2) | 0.99 (0.60–1.62) | 1.04 (0.63–1.72) |
Valvular heart disease | 70 | 60.0 (48.8–71.4) | 2.44 (1.79–3.34) | 1.73 (1.26–2.38) |
Myocardial infarction | 85 | 41.2 (31.6–52.4) | 1.45 (1.04–2.05) | 1.17 (0.83–1.65) |
Atrial fibrillation | 66 | 50.0 (38.7–62.5) | 1.81 (1.27–2.57) | 1.21 (0.85–1.73) |
None of the above | 117 | 41.0 (32.7–50.5) | 1.46 (1.09–1.95) | 1.12 (0.83–1.50) |
CHF severityb | ||||
CHF absent | 2248 | 30.4 (28.6–32.4) | 1.00 (ref.) | 1.00 (ref.) |
Non-users | 99 | 32.2 (24.1–42.5) | 1.08 (0.76–1.54) | 0.99 (0.69–1.42) |
Low dose (≤40 mg/day) | 39 | 38.5 (25.3–55.5) | 1.30 (0.78–2.16) | 0.83 (0.50–1.40) |
Medium dose (41–80 mg/day) | 82 | 42.7 (32.8–54.1) | 1.52 (1.08–2.14) | 1.13 (0.80–1.59) |
High dose (81–159 mg/day) | 75 | 53.3 (42.6–64.9) | 2.05 (1.49–2.83) | 1.55 (1.11–2.14) |
Very high dose (≥160 mg/day) | 95 | 54.7 (45.1–64.9) | 2.10 (1.59–2.79) | 1.62 (1.21–2.18) |
Duration of CHF | ||||
CHF absent | 2248 | 30.4 (28.6–32.4) | 1.00 (ref.) | 1.00 (ref.) |
< 3 years | 188 | 50.0 (43.1–57.3) | 1.83 (1.48–2.27) | 1.43 (1.14–1.78) |
≥ 3- < 6 years | 81 | 39.5 (29.8–51.0) | 1.39 (0.98–1.99) | 1.01 (0.71–1.46) |
≥ 6- < 10 years | 69 | 42.0 (31.4–54.5) | 1.52 (1.05–2.21) | 1.22 (0.84–1.78) |
≥ 10 years | 52 | 36.5 (25.1–51.1) | 1.25 (0.79–1.97) | 0.97 (0.61–1.54) |